Leanna Lui

Researcher/author in psychiatry at the University of Toronto

Data updated

Papers

8 publications

Trials

0 clinical trials

Research Footprint

Leanna Lui appears in 8 tracked papers (2018–2022), most studied alongside Ketamine, Esketamine and MDMA, across Depressive Disorders, Suicidality and Treatment-Resistant Depression (TRD).

Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).

Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Roger Ho.

Background & Research

Leanna M. W. Lui appears to be a psychiatry researcher based at the University of Toronto and has coauthored multiple papers on ketamine, esketamine, suicidality, and treatment-resistant depression. Her publications include systematic reviews and real-world analyses relevant to rapid-acting antidepressant and psychedelic-adjacent clinical research.

Key Impact

She co-authors systematic reviews and clinical studies on ketamine and esketamine for depression, suicidality, and related adverse effects, contributing to the evidence base in psychedelic and rapid-acting antidepressant research.

8

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

24 collaborators· click a node to visit their profile

Full network →

Compounds

KetamineEsketamineMDMAPsilocybin

Topics

Depressive DisordersSuicidalityTreatment-Resistant Depression (TRD)Major Depressive Disorder (MDD)Anxiety DisordersBipolar DisorderNeurocognitive DisordersAlcohol Use Disorder (AUD)Substance Use Disorders (SUD)Equity and EthicsAdolescentsPublic Health, Prevention & Behaviour ChangeChronic PainHealthy VolunteersSafety & Risk ManagementMedicinal Chemistry & Drug DevelopmentHealth Economics & ReimbursementNeuroimaging & Brain MeasuresImmunology & InflammationPTSD

Top Collaborators

Affiliations

Institutions, companies, and organisations Leanna Lui is associated with.

University of Toronto

University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.

View stakeholder →

University Health Network, Toronto

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

View stakeholder →